Document is current
Any future updates will be listed below
-
Authors
Nicola, Teodora
Wenger, Nancy M.
Seidman, Kara
Evans, Michael
Yang, Youfeng
Chen, Dongquan
Van Der Pol, William J.
Walia, Amar
Lefkowitz, Elliot J.
Wang, Jun
LeMoire, Ashley
Lin, Lois
Morrow, Casey
Ambalavanan, Namasivayam
Gaggar, Amit
Lal, Charitharth Vivek
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05523180 at ClinicalTrials.govDocuments that mention this clinical trial
Double-Blind Randomized Placebo-Controlled Trial of a Lactobacillus Probiotic Blend in Chronic Obstructive Pulmonary Disease
https://doi.org/10.1007/s41030-025-00333-y
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (K08 HL141652)
National Heart, Lung, and Blood Institute (R44HL164156)
National Center for Advancing Translational Sciences (UM1TR004771)
- License Information
-
More Information
Article History
Received: 8 September 2025
Accepted: 31 October 2025
First Online: 18 November 2025
Declarations
:
: Charitharth Vivek Lal is Founder of ResBiotic Nutrition Inc. Amit Gaggar is Chief Medical Officer of ResBiotic Nutrition Inc. Namasivayam Ambalavanan is an Advisor to ResBiotic Nutrition Inc. All other authors (Teodora Nicola, Nancy M. Wenger, Kara Seidman, Michael Evans, Youfeng Yang, Dongquan Chen, William J. Van Der Pol, Amar Walia, Elliot J. Lefkowitz, Jun Wang, Ashley LeMoire, Lois Lin, Casey Morrow) declare that they have nothing to disclose. The authors further confirm that the research was conducted by an independent, third-party contract research organization, in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: This study was approved by the Sterling Institutional Review Board (Atlanta, GA, USA; Protocol 10163-MASTER) and was conducted in accordance with the Declaration of Helsinki and applicable regulatory requirements. All participants provided written informed consent prior to enrollment.
